Latest Nitriles Stories

Lawyers will update judge about consolidated federal litigation involving hundreds of lawsuits claiming SSRI anti-depressant use allegedly caused birth defects. Free consultations about legal options are now available to consumers. San Diego, CA (PRWEB) May 17, 2013 http://www.resource4thepeople.com/defectivedrugs/zoloft.html Resource4thePeople today announced it is providing consumers its latest update about consolidated federal lawsuits* involving allegations that the use of Zoloft or...

April Flowers for redOrbit.com - Your Universe Online A new study from the Ann Arbor Veterans Health Administration (VA) Healthcare System and the University of Michigan reveals the US Food and Drug Administration’s (FDA) warning that high doses of citalopram, also known as Celexa, can cause potentially serious abnormal heart rhythms might be doing more harm than good. The FDA attached a warning to the antidepressant in 2011, based on data linking higher doses of the drug to...

U.S. Naval Research Laboratory U.S. Naval Research Laboratory Chemistry Division scientists have developed a second generation, cost-effective polyetheretherketone (PEEK)-like phthalonitrile-resin demonstrating superior high temperature and flammability properties for use in numerous marine, aerospace, and domestic applications. The resin can be used to make composite components by established industrial methods such as resin transfer molding (RTM), resin infusion molding (RIM),...

Lawrence LeBlond for redOrbit.com - Your Universe Online Some antidepressants, known as selective serotonin reuptake inhibitors (SSRIs), have been found to pose a small but serious risk on users’ hearts, according to new research. These drugs, which include citalopram and escitalopram, have been found to trigger a disturbance in QT interval (the duration of electrical activity of the heart muscle) heart rhythms. The research, published today in the British Medical Journal, supports...

MISSISSAUGA, ON, Dec. 21, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today announced that the Supreme Court of Nova Scotia has granted an interim order, setting, among other things, December 31, 2012 as the record date associated with the previously announced plan of arrangement. Every shareholder of record at the close of business on that day will be entitled to receive notice of and vote at the special meeting of YM shareholders ("Meeting") at which they will...

- 68% transfusion independence response rate and 37% durable spleen response rate - MISSISSAUGA, ON, Dec. 9, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported updated results from the 166 patient Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results were presented this afternoon in an oral session at the 54(th) Annual Meeting of the American Society of Hematology underway in Atlanta, Georgia....

Prostate cancer drug shows promise in triple-negative and estrogen-positive breast cancer Breast cancers are defined by their drivers – estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options – this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative. A decade ago, work at...

MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys PTE Ltd., a company based in Singapore, for undisclosed consideration including an immediate US$2 million payment. CIMYM was a joint venture subsidiary 80% owned by YM BioSciences and 20% owned by CIMAB S.A. (representing Centro de Inmunología Molecular, Cuba). CIMAB S.A. has reported it has...

MISSISSAUGA, ON, Nov. 20, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today announced that Kapil Dhingra has been elected by shareholders to the Company's Board of Directors at YM's Annual Meeting of Shareholders held this afternoon. Dr. Dhingra has 25 years of experience in oncology clinical research and drug development. Previously, Dr. Dhingra held the position of Vice President,...

MISSISSAUGA, ON, Nov. 5, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today reported interim results from the Phase I/II study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, which were included in an abstract submitted to the American Society of Hematology in August 2012. Updated results will be presented in an Oral Session at the 2012...